The synthesis and SAR of a series of 60 substituted 2-phenoxy-5-nitrobenzonitriles (analogues of MDL-860) as inhibitors of enterovirus replication (in particular of coxsackievirus B3 (CVB 3)) are reported. Several of the analogues inhibited CVB 3 and other enteroviruses at low-micromolar concentrations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2008.07.099 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
N-Acetylcysteine Inhibits Coxsackievirus B3 Replication by Downregulating Eukaryotic Translation Elongation Factor 1 Alpha 1.
Viruses
September 2024
Department of Cell Biology, Harbin Medical University, 157 Baojian Road, Harbin 150081, China.
Article Synopsis
- Group B Coxsackieviruses (CVB) can lead to myocarditis and potentially cardiomyopathy, but there's currently no effective antiviral treatment available.
- The study investigates the effects of N-acetylcysteine (NAC), an antioxidant, which was found to significantly reduce viral replication and cardiac injury caused by CVB3.
- The research reveals that NAC downregulates a specific protein, eEF1A1, that facilitates viral replication in infected cells, and promotes its degradation through autophagy, contributing to its antiviral effects.
Coxsackievirus infection induces direct pancreatic β cell killing but poor antiviral CD8 T cell responses.
Sci Adv
March 2024
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β cell autoimmunity and type 1 diabetes. We investigated how CVB affects human β cells and anti-CVB T cell responses. β cells were efficiently infected by CVB in vitro, down-regulated human leukocyte antigen (HLA) class I, and presented few, selected HLA-bound viral peptides.
View Article and Find Full Text PDFSafety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial.
Diabetologia
May 2024
Provention Bio, Inc., a Sanofi Company, Bridgewater, NJ, USA.
Aims/hypothesis: Infection with coxsackie B viruses (CVBs) can cause diseases ranging from mild common cold-type symptoms to severe life-threatening conditions. CVB infections are considered to be prime candidates for environmental triggers of type 1 diabetes. This, together with the significant disease burden of acute CVB infections and their association with chronic diseases other than diabetes, has prompted the development of human CVB vaccines.
View Article and Find Full Text PDFCoxsackievirus infection induces direct pancreatic β-cell killing but poor anti-viral CD8+ T-cell responses.
bioRxiv
August 2023
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France.
Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β-cell autoimmunity. We investigated how CVB impacts human β cells and anti-CVB T-cell responses. β cells were efficiently infected by CVB , downregulated HLA Class I and presented few, selected HLA-bound viral peptides.
View Article and Find Full Text PDFN-Acetyl cysteine effectively alleviates Coxsackievirus B-Induced myocarditis through suppressing viral replication and inflammatory response.
Antiviral Res
July 2020
Department of Cell Biology, Harbin Medical University, 157 Baojian Road, Harbin, 150081, China. Electronic address:
Viral myocarditis caused by Coxsackievirus B (CVB) infection is a severe inflammatory disease of the myocardium, which may develop to cardiomyopathy and heart failure. No effective specific treatment is available. Our previous study demonstrated that suppression of proinflammatory caspase-1 activation effectively inhibited CVB replication.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!